Literature DB >> 6622506

The discriminative stimulus properties of cocaine in the rhesus monkey.

R D Garza, C E Johanson.   

Abstract

Three rhesus monkeys were trained to discriminate IM injections of cocaine (0.25 mg/kg) from saline under conditions where responding was maintained on one of two levers under a fixed-ratio 30 schedule of food delivery. The ability of other doses of cocaine and other compounds to substitute for the training dose of cocaine in controlling cocaine-appropriate responding was assessed. Cocaine (0.008-0.5 mg/kg), d-amphetamine (0.03-0.25 mg/kg) and l-cathinone (0.03-0.5 mg/kg) produced dose dependent increases in the percent of cocaine-appropriate responding in test sessions. At the highest doses tested, these three compounds produced more than 90% cocaine-appropriate responding suggesting that they share discriminative stimulus properties. When nicotine (0.125-16 mg/kg) and procaine (0.06-8.0 mg/kg) were tested, some of the monkeys responded 90% or more on the cocaine-appropriate lever; in other cases there was a trend towards generalization at lower doses but when higher doses were administered, responding was suppressed. These data suggest that these two compounds have discriminative stimulus properties which differ to some extent from cocaine. Finally, when pentobarbital (2-16 mg/kg) was administered, responding occurred on the saline-appropriate lever indicating that this drug does not share the discriminative stimulus properties of cocaine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6622506     DOI: 10.1016/0091-3057(83)90323-4

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  22 in total

1.  Toward a functional analysis of delusional speech and hallucinatory behavior.

Authors:  T V Layng; P T Andronis
Journal:  Behav Anal       Date:  1984

Review 2.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

3.  Neural response to lidocaine in healthy subjects.

Authors:  Bryon Adinoff; Michael D Devous; Donald C Cooper; Susan E Best; Thomas S Harris; Mark J Williams
Journal:  Psychiatry Res       Date:  2009-06-28       Impact factor: 3.222

4.  Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats.

Authors:  Rajeev I Desai; David J Barber; Philip Terry
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

5.  Discriminative and reinforcing stimulus effects of nicotine, cocaine, and cocaine + nicotine combinations in rhesus monkeys.

Authors:  Nancy K Mello; Jennifer L Newman
Journal:  Exp Clin Psychopharmacol       Date:  2011-06       Impact factor: 3.157

6.  The puzzle of drug-induced conditioned taste aversion: comparative studies with cathinone and amphetamine.

Authors:  A J Goudie; T Newton
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 7.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1982-1983.

Authors:  I P Stolerman; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Cocaine-like discriminative stimulus effects of amphetamine, cathinone, methamphetamine, and their 3,4-methylenedioxy analogs in male rhesus monkeys.

Authors:  Douglas A Smith; Bruce E Blough; Matthew L Banks
Journal:  Psychopharmacology (Berl)       Date:  2016-10-05       Impact factor: 4.530

Review 9.  Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Curr Top Behav Neurosci       Date:  2018

10.  Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Authors:  Colin S Cunningham; Megan J Moerke; Martin A Javors; F Ivy Carroll; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.